Literature DB >> 9835617

Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression.

D W McGraw1, S L Forbes, L A Kramer, S B Liggett.   

Abstract

Cellular expression of the beta2-adrenergic receptor (beta2AR) is controlled in part by a 19-amino acid peptide that regulates mRNA translation. This peptide is encoded by a short open reading frame, termed the 5' leader cistron (5'LC), which is 102 bp upstream of the beta2AR coding block. In 176 normal subjects we found a single nucleotide polymorphism resulting in either Arg (previously denoted wild-type) or Cys at position 19 of this peptide. Allele frequencies were 0.37 for Arg and 0.63 for Cys. To determine if these variants altered beta2AR expression, COS-7 cells were transfected with polymorphic constructs consisting of 1,989 bp encompassing the 5'LC and the beta2AR coding block exactly as found in the human gene. beta2AR density, as determined by [125I]CYP radioligand binding, was 72% higher in cells transfected with the 5'LC-Cys19 construct as compared with those transfected with the 5'LC-Arg19 construct and 110% higher when a cotransfection technique with a luciferase construct was used to control for transfection efficiency. Levels of the two mRNA transcripts were not different, confirming in vitro studies that the upstream peptide regulates receptor expression at the translational level. In human airway smooth muscle cells that natively express beta2AR, receptor expression was approximately twofold higher in those bearing the Cys versus the Arg polymorphism, confirming the phenotype in a relevant cell type. Linkage disequilibrium was observed between the 5'LC-Cys polymorphism and the beta2AR coding block polymorphisms Arg16 and Gln27 (P < 0.0001), although several different haplotypes were identified. Thus, beta2AR expression in the human population is controlled by a common polymorphism of this 5'LC, and may be responsible for interindividual variation in betaAR responsiveness.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9835617      PMCID: PMC509144          DOI: 10.1172/JCI4862

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Delineation of the intronless nature of the genes for the human and hamster beta 2-adrenergic receptor and their putative promoter regions.

Authors:  B K Kobilka; T Frielle; H G Dohlman; M A Bolanowski; R A Dixon; P Keller; M G Caron; R J Lefkowitz
Journal:  J Biol Chem       Date:  1987-05-25       Impact factor: 5.157

2.  The peptide product of a 5' leader cistron in the beta 2 adrenergic receptor mRNA inhibits receptor synthesis.

Authors:  A L Parola; B K Kobilka
Journal:  J Biol Chem       Date:  1994-02-11       Impact factor: 5.157

3.  Arginine-mediated RNA recognition: the arginine fork.

Authors:  B J Calnan; B Tidor; S Biancalana; D Hudson; A D Frankel
Journal:  Science       Date:  1991-05-24       Impact factor: 47.728

4.  Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype.

Authors:  J Turki; J Pak; S A Green; R J Martin; S B Liggett
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

5.  USE OF ALKYLTRIMETHYLAMMONIUM BROMIDES FOR THE ISOLATION OF RIBO- AND DESOXYRIBO-NUCLEIC ACIDS.

Authors:  A S JONES
Journal:  Nature       Date:  1963-07-20       Impact factor: 49.962

6.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

7.  Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects.

Authors:  E Reihsaus; M Innis; N MacIntyre; S B Liggett
Journal:  Am J Respir Cell Mol Biol       Date:  1993-03       Impact factor: 6.914

8.  Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties.

Authors:  S A Green; J Turki; M Innis; S B Liggett
Journal:  Biochemistry       Date:  1994-08-16       Impact factor: 3.162

9.  Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to stimulate adenylyl cyclase.

Authors:  W Rosenthal; A Antaramian; S Gilbert; M Birnbaumer
Journal:  J Biol Chem       Date:  1993-06-25       Impact factor: 5.157

10.  A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor.

Authors:  S A Green; G Cole; M Jacinto; M Innis; S B Liggett
Journal:  J Biol Chem       Date:  1993-11-05       Impact factor: 5.157

View more
  58 in total

1.  High-throughput genotyping with single nucleotide polymorphisms.

Authors:  K Ranade; M S Chang; C T Ting; D Pei; C F Hsiao; M Olivier; R Pesich; J Hebert; Y D Chen; V J Dzau; D Curb; R Olshen; N Risch; D R Cox; D Botstein
Journal:  Genome Res       Date:  2001-07       Impact factor: 9.043

Review 2.  Genetic polymorphisms of adrenergic receptors.

Authors:  E M Garland; I Biaggioni
Journal:  Clin Auton Res       Date:  2001-04       Impact factor: 4.435

3.  Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism.

Authors:  D R Taylor; J M Drazen; G P Herbison; C N Yandava; R J Hancox; G I Town
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

Review 4.  Pharmacogenetics and the future of medical practice.

Authors:  Klaus Lindpaintner
Journal:  J Mol Med (Berl)       Date:  2003-03-25       Impact factor: 4.599

5.  Beta 2 adrenergic receptor 5' haplotypes influence promoter activity.

Authors:  Sharon E Johnatty; Maha Abdellatif; Lawrence Shimmin; Richard B Clark; Eric Boerwinkle
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

6.  Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins.

Authors:  Rohit Loomba; Fangwen Rao; Lian Zhang; Srikrishna Khandrika; Michael G Ziegler; David A Brenner; Daniel T O'Connor
Journal:  Gastroenterology       Date:  2010-06-09       Impact factor: 22.682

Review 7.  Pharmacogenetics of asthma.

Authors:  John J Lima; Kathryn V Blake; Kelan G Tantisira; Scott T Weiss
Journal:  Curr Opin Pulm Med       Date:  2009-01       Impact factor: 3.155

8.  Limited impact of multiple 5' single-nucleotide polymorphisms on the transcriptional control of the human beta 2-adrenoceptor gene.

Authors:  Robert Westland; Anneke van Veen; Henk M Jansen; Rene E Jonkers; Eddy A Wierenga
Journal:  Immunogenetics       Date:  2004-11-17       Impact factor: 2.846

Review 9.  Pharmacogenetics of the beta 2-adrenergic receptor gene.

Authors:  Victor E Ortega; Gregory A Hawkins; Stephen P Peters; Eugene R Bleecker
Journal:  Immunol Allergy Clin North Am       Date:  2007-11       Impact factor: 3.479

10.  Selective inhibition of angiotensin receptor signaling through Erk1/2 pathway by a novel peptide.

Authors:  Jun Liu; Gina L C Yosten; Hong Ji; Dan Zhang; Wei Zheng; Robert C Speth; Willis K Samson; Kathryn Sandberg
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-02-12       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.